An interventional study of Parathyroid surgery in Primary Hyperparathyroidism, sponsored by Region Skane. Completed at 1 site in Sweden. Open to participants aged 66 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Region Skane · Not applicable, Interventional, and Treatment
General consensus and contemporary guidelines, recommend surgery for primary hyperparathyroidism (pHPT)for all patients below the age of 50, for patients with pronounced hypercalcemia and for patients with organ complications to the disease (osteoporosis and decreased renal function).
The purpose of this study is to determine if surgery for pHPT, is appropriate for patients with moderate to mild hypercalcemia older than 65 years of age.
The hypothesis of the study is that surgery for pHPT in patients older than 65 years of age, and with mild hypercalcemia, will increase bone density and hence decrease future risk for fragility fractures compared to patients with follow-up only.
The majority of patients diagnosed and operated due to primary HPT in Scandinavia are older than 65 years of age. The vast majority of the patients have mild aberrations of serum calcium (\< 1.50 mmol/l ionized calcium), and some patients may even be asymptomatic. The present trial is designed to clarify the indications for surgical treatment in this large subgroup of patients.
104 studies on the registry are indexed under Hyperparathyroidism, Primary; 23 are open to participants now.
This study's enrollment of 102 is above the median of 68 across 60 interventional studies indexed under Hyperparathyroidism, Primary.
Browse Hyperparathyroidism, Primary studies →Region Skane is the lead sponsor of 386 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are followed only
Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are treated with parathyroid surgery
Procedure: Parathyroid surgery
Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
Also known as: BA
Bone density at the hip
Bone density is assessed with DEXA (dual energy x-ray absorptiometry), at the hip.
Time frame: At two years
Bone density at the lumbar spine
Bone density is assessed with DEXA (dual energy x-ray absorptiometry) at the lumber spine
Time frame: At two years
Blood lipids
Triglyceride and cholesterol concentrations of whole serum and of the lipoprotein classes; low-density-lipoprotein (LDL), very-low-density-lipoprotein (VLDL) and high-density-lipoprotein (HDL).
Time frame: At two years
Cardiac function
Cardiac function assessed with echocardiography; Left ventricular ejection fraction (EF), Left ventricular end-diastolic diameter (LVDD), Left ventricular mass index (LVMI), Ratio between mitral peak velocity flow of the early filling wave and the atrial filling wave (E/A ratio).
Time frame: At two years
Cognitive function
Mini Mental State Examination test (MMSE), for cognitive function. A Quich Test (AQT), for cognitive speed
Time frame: At two years
Atherosclerosis
Carotid ultrasound/duplex scans with evaluation of intimal-medial thickness and plaques.
Time frame: At one two years
Oral glucose tolerance
Oral glucose tolerance test (75 Gram), with measurement of blood glucose and insulin after 60, 120 and 180 min.
Time frame: At two years
Blood pressure (systolic and diastolic)
24 hours blood pressure measurement
Time frame: At two years
Renal function
GFR measured by the clearance of iohexol and urinary albumin excretion
Time frame: At two years
Ran from Aug 2010 to primary completion in Jun 2025, 178 months.
Of 20 interventional studies with no phase under Hyperparathyroidism, Primary, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 84. This study's 178 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperparathyroidism, Primary →